Thus, future studies should also focus on biomarkers in both prostate stromal cells and epithelial cells that indicate when treatment with TGF-β inhibitors are safe and beneficial during early prostate tumorigenesis for the blockade of tumor growth and metastasis. Here, TGFB1 is linked to neoplasm.